Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues

被引：37

作者：

Gillis, N. K. ^{[1
]}

Innocenti, F. ^{[1
,2
]}

机构：

[1] Univ N Carolina, Eshelman Sch Pharm, Ctr Pharmacogen & Individualized Therapy, Chapel Hill, NC 27514 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 96卷 / 06期

关键词：

D O I：

10.1038/clpt.2014.185

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics is an area of research that has potential to greatly benefit patients. However, the routine use of diagnostic pharmacogenetic testing to inform treatment decisions is limited. Here we discuss the determination of clinical utility of pharmacogenetic testing and the level of evidence required to support translation into clinical practice.

引用

页码：655 / 657

页数：3

共 10 条

[1] Debating Clinical Utility [J].